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Abstract
Background: Covered coronary stent (CS) implantation is associated with a high risk for in-stent 
restenosis (ISR) and stent thrombosis (ST). We describe the outcomes after overstenting (“burying”) 
CS using contemporary drug-eluting stents (DES).
Methods: We analyzed short- and long-term outcomes of consecutive patients who had had a CS im-
planted, which was consecutively covered (“buried”) with a third-generation DES. CSs were primarily 
post-dilated and then covered with a longer DES overlapping the proximal and distal edges of the CS. 
To ensure optimal stent expansion and appositions, all lesions were post-dilated using adequately sized 
non-compliant balloons. 
Results: Between 2015 and 2020, 23 patients (mean age 67 ± 14 years, 74% males) were treated us-
ing this novel approach. Reasons for implanting CS included treatment of coronary aneurysms (n = 7; 
30%), coronary perforations (n = 13; 57%), and aorto-ostial dissections (n = 3; 13%). All CSs were 
successfully deployed, and no peri-procedural complications occurred. The median time of follow-up 
was 24.5 (interquartile range [IQR] 11.7–37.9) months. All patients had a 1-month follow-up (FU) 
and 19/23 (83%) patients had 12-month FU (FU range 1–60 months). No probable or definite STs 
occurred, and no cardiovascular deaths were observed. Among patients undergoing angiographic FU 
(11/23 [48%]), 1/23 showed angiographically significant ISR 6 months post CS implantation. 
Conclusions: Burying a coronary CS under a DES appears to be a safe and promising strategy to 
overcome the limitations of the currently available CS devices, including a relatively high risk for target 
lesion failure due to ISR and ST. (Cardiol J)
Key words: stents, covered stent, aneurysm, perforation, target lesion failure, in-stent 
restenosis, percutaneous coronary intervention
Introduction
Coronary covered stents (CS) — stent devices 
covered with synthetic or biological membranes — 
are generally used to seal coronary perforations [1] 
or exclude coronary aneurysms [2]. While they 
are potentially lifesaving in the acute setting, 
high rates of in-stent-restenosis (ISR) and stent 
thrombosis (ST) have been observed during mid- 
and long-term follow-up [3–7]. Indeed, a recent 
multicenter registry analysis indicated target le-
sion revascularization (TLR) and ST rates of 5% 
and 3%, respectively, after a mean follow-up of 
22 ± 16 months [7].
The vascular healing of the CS’ synthetic mate-
rial represents a complex process, and the contact of 
the surface of the implanted stent graft material with 
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cells triggers pro-thrombotic processes [8]. 
Additionally, intimal hyperplasia is uncontrolled and 
leads to ISR [9]. In contrast, the latest generation 
of drug-eluting stents (DES) and their antiprolif-
erative properties have tremendously improved 
angiographic and clinical outcomes of patients un-
dergoing percutaneous coronary intervention (PCI) 
with stent implantation. Those advancements are 
attributable to thinner metallic stent platforms, 
novel biocompatible polymer technologies, and 
potent antiproliferative drugs, which improve 
reendothelialization and therefore mitigate the risk 
for target lesion failure [10, 11]. 
In this context, combining contemporary CS 
with novel DES, by over-stenting (“burying”) the 
covered stent under the DES, might help to over-
come the limitations related to CS and achieve 
better short- and long-term outcomes. We describe 
short- and long-term results of this novel approach 




This analysis derives from the ongoing retro-
spective L-CAD registry, which was established 
to assess procedural characteristics and outcomes 
of patients requiring PCI for complex coronary le-
sions. This registry complies with the Declaration 
of Helsinki and was approved by the regional ethics 
committee (BASEC ID 2019-01067). Patients pro-
vided written informed consent for data collection. 
We analyzed consecutive patients with coro-
nary aneurysms or coronary perforations, who 
were treated with the novel approach of combining 
CS and DES between February 2015 and March 
2020. All patients were treated for acute or chronic 
coronary syndromes at the Cardiology Division of 
the Luzerner Kantonsspital (Lucerne, Switzer-
land), a tertiary cardiology facility in Switzerland, 
which performs annually more than 1600 PCIs. 
Percutaneous coronary intervention
All patients were treated according to our 
local PCI protocol using a radial or femoral ap-
proach. We administered unfractionated heparin 
in a weight-adapted dosage (70 U/kg) and ensured 
that all patients received guideline-recommended 
dual antiplatelet therapy including acetylsalicylic 
acid (ASA) plus a loading dose of clopidogrel, tica-
grelor, or prasugrel for 12 months. In patients 
who required anticoagulation, we administered 
periprocedural ASA and prescribed a novel oral 
anticoagulant in combination with clopidogrel for 
12 months. The patients were otherwise treated 
according to guideline recommendations for acute 
or chronic coronary syndromes. 
The PCI procedures were performed accord-
ing to the involved physician’s preferences. Of 
note, our institution routinely uses non-compliant 
balloons at high pressure (> 18 atm) for pre-dila-
tation. For heavily calcified lesions, dedicated tools 
including rotational atherectomy, scoring balloons, 
and/ or ultra-high-pressure non-compliant balloons 
(OPN™, SIS Medical, Frauenfeld, Switzerland) 
were used. 
Patients with coronary perforations were 
admitted to our recovery area or cardiac care 
unit for surveillance and received serial follow-up 
echocardiograms. 
Coronary covered stent devices
The choice of CS device used for the treatment 
of a coronary perforation or aneurysm was left to 
the involved physician’s discretion. We implanted 
either polytetrafluoroethylene or polyurethane 
CSs. Expanded polytetrafluoroethylene (ePTFE) 
is a synthetic fluorocarbon polymer with a broad 
range of applications in medicine, including the 
manufacture of vascular grafts. The ePTFE-based 
BeGraft™ coronary stent graft system (Bentley 
Innomed GmbH, Hechingen, Germany) combines 
a single layer cobalt-chromium stent platform with 
an ePTFE membrane clamped at the stent ends 
[12]; whereas, polyurethanes are known for their 
excellent biocompatibility in combination with 
their well-known physiochemical and mechani-
cal properties [12]. They are commonly used in 
cardiovascular applications, such as heart valves 
and pacemaker leads. Polyurethane-covered stents 
have been in use for the peripheral vasculature for 
decades. The polyurethane-based PK Papyrus™ 
coronary stent system (Biotronik, Bülach, Swit-
zerland) combines a stent platform, covered by 
a 90 µm thick polymer using electrospinning tech-
nology that yields a thinner and relatively flexible 
material [12]. The detailed characteristics of both 
devices are shown in Table 1. 
To cover those CS devices, we used third-
-generation DES, preferably cobalt-chromium 
based sirolimus- or everolimus-eluting coronary 
stent systems (Orsiro™ or Xience Alpine/ Sierra™ 
DES devices, respectively). Notably, the DES was 
longer than the covered stent, which meant that the 
covered stent was completely “buried” at both ends 
(overhanging the edges). Post-dilatation was per-
formed in all patients using non-compliant balloons 
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in order to achieve optimal stent expansion and ap-
position. For post-dilatation, the balloon-diameter 
is usually selected either on visual estimation (if 
possible, applying a balloon-to-vessel ratio of 1:1) 
or based upon optical coherence tomography (OCT) 
measurement at our site. In selected cases with 
underlying heavy calcifications resulting in residual 
stent under-expansion, we might choose an OPN™ 
non-compliant balloon at very high pressure (30– 
–50 atm) using a diameter 0.5 mm smaller than the 
estimated/measured vessel size.
Data collection and outcome definitions
Information about the patient characteristics, 
including previous medical history and medication, 
vital parameters, laboratory values, PCI indication, 
as well as periprocedural findings/management 
were collected by chart review. Lesion charac-
teristics were classified according to the Ameri-
can College of Cardiology (ACC) and American 
Heart Association (AHA) lesion classification [13]. 
Coronary calcifications were identified as easily 
apparent radiopacities within the vascular wall at 
the site of the lesions and were classified as none/ 
/mild, moderate (radiopacities noted only dur-
ing the cardiac cycle before contrast injection), 
and severe (radiopacities observed without car-
diac motion prior to contrast injection commonly 
compromising both sides of the arterial lumen) 
[14]. Chronic total occlusions were defined as 
a more than three-month-old obstruction of native 
coronary arteries, free of any luminal continuity, and 
thrombolysis in myocardial infarction (TIMI) flow 0.
Coronary perforations were graded according 
to the Ellis Classification: Type I, Extraluminal 
crater without extravasation; Type II, Pericardial 
or myocardial blush without contrast jet extrava-
sation; Type III, Extravasation through frank 
(> 1 mm) perforation; and Type III, cavity spilling, 
cavity perforation into an anatomic cavity chamber, 
spilling coronary sinus, etc. [15]. 
Our clinical endpoints of interest included 
death from any cause, cardiac death, target ves-
sel revascularization (TVR) myocardial infarction 
(MI), clinically driven TLR, and ST [16]. Cardiac 
death and clinically driven TLR were defined as 
suggested by the Academic Research Consortium 
(ARC) criteria [17, 18]. For MI, we applied the uni-
versal definition [16]. ST was classified as definite, 
probable, and possible [17, 18].
Follow-up information was collected by chart 
review and from visits to our clinics. All coronary 
angiograms and OCT runs were reviewed and 
adjudicated by M.B. and F.C. 
OCT acquisition and analysis
In the case of TVR, our internal protocol sug-
gested an OCT if possible. OCT investigations 
were acquired before and optimally after PCI. For 
OCT, we used the Optis Ilumien™ system and the 
Dragon Fly Duo OCT Imaging Catheter (St. Jude 
Medical/Abbott Vascular, Santa Clara, CA) with mo-
torized pullback (25 mm/s) using a non-occlusive 
flushing technique according to the manufacturer’s 
recommendations. Images of the CS and of the ref-
erence segments 10 mm proximal and distal of the 
previously implanted stent devices were acquired. 
OCT pullbacks were registered and assessed of-
fline using dedicated software (OPTIS™ Imaging 
Software, Abbott Vascular, Santa Clara, CA). We 





Graft material ePTFE Electrospun polyurethane
Stent material/design CoCr (L-605)  
Single layer
CoCr (L-605) with silicon carbide coating 
Single layer
Guide catheter compatibility 5 Fr 5 Fr (stents < 4.0 mm) 
6 Fr (stents ≥ 4.0 mm)
Crimped profile [mm] 1.1–1.4 1.18–1.55
Stent diameters [mm] 2.5–5.0 2.5–5.0
Stent lengths [mm] 8–24 15–26
Nominal implantation  
pressure [atm]
11 atm (2.5–4.0 mm) 
10 atm (4.5–5.0 mm)
8 atm (2.5–3.5 mm) 
7 atm (4.0–5.0 mm)
Information obtained from product catalogues and Kilic et al. [12]; atm — atmospheres; CoCr — cobalt-chromium; ePTFE — expanded 
polytetrafluoroethylene; Fr — French
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applied the same methodology and definitions as 
described elsewhere earlier [18]. 
Statistical methodology
Categorical variables are displayed as absolute 
numbers and percentages, and continuous variables 
are presented as means (± standard deviations) 
or medians (interquartile ranges [IQR]), as ap-
propriate.
Results
A total of 23 consecutive patients were in-
cluded in this registry over a period of 5 years 
(2015–2020). Baseline characteristics of the study 
population are depicted in Table 2. In brief, the 
mean age was 67 ± 14 years, and most of the pa-
tients were male (74%). Half (52%) of the patients 
presented with a stable angina equivalent (chronic 
coronary syndrome), while the remaining had an 
acute coronary syndrome. 
Procedural characteristics
The indication for the use of CS, lesion char-
acteristics, and details of the procedures are sum-
marized in Table 3. The reasons for implantation 
of CS included treatment of coronary aneurysms, 
coronary perforations, and deep dissections at the 
ostium of the right coronary artery among 7 (30%) 
patients, 13 (57%) patients, and 3 (13%) patients, 
respectively. Two illustrative case vignettes are 
highlighted in Figure 1 and 2. 
In total, 24 CS devices were deployed: 13 
(54%) Papyrus™ and 11 (46%) BeGraft™ devices. 
The mean size and length of the CS devices were 
3.6 ± 0.6 mm and 19.1 ± 3.8 mm, respectively. The 
CS were covered with a total of 52 DES with a mean 
size and length of 3.6 ± 0.5 mm and 30.2 ± 7.7 mm. 
All stents were post-dilated using adequately sized 
non-compliant balloons (mean balloon size 3.9 ± 
± 0.4 mm, mean inflation pressure 19 ± 6 atm). 
In 12 (52%) patients, the coronary CS was 
directly deployed at the site of native lesion and 
then covered using a DES. All patients undergo-
ing treatment of a coronary aneurysm (n = 7) and 
5 patients with coronary perforations (Ellis type 2–3) 
after lesion preparation were treated by apply-
ing the following sequence: CS Æ DES. Among 
11 patients, coronary perforation/rupture occurred 
after DES implantation (particularly after post-
dilatation). In those scenarios, the CS was used 
to seal the perforation site and stop the bleeding. 
The DES was implanted to finally cover the CS 
(sequence: DES Æ CS Æ DES).
Outcomes
The median time of follow-up was 24.5 (IQR 
11.7–37.9) months. Short- and long-term out-
comes are summarized in Table 4. No patients 
experienced probable or definite ST. Only 1 patient 
required TLR due to clinically significant ISR 
6 months after CS implantation. In this case, 
a coronary perforation had occurred after treatment 
of a highly calcified ostial RCA lesion (the treat-
ment sequence at the index procedure was DES 
Æ CS Æ DES). In this specific case, we identified 
recoil in combination with neo-intima formation as 
the mechanisms leading to ISR. Consequently, we 
Table 2. Baseline characteristics of the study 
population (n = 23).
Age [years] 67 ± 14
Female sex 6/23 (26%)
Cardiovascular risk factors:





Previous myocardial infarction 9/23 (39%)
Previous PCI 8/23 (35%)
Previous CABG 1/23 (4%)
Established renal failure* 7/23 (30%)
Left ventricular ejection fraction [%] 53 ± 7
Clinical presentation:
Stable angina equivalent (CCS) 12/23 (52%)
Unstable angina/NSTEMI 9/23 (39%)
STEMI 2/23 (9%)
Access management:
Radial approach 15/23 (65%)









*Defined as estimated glomerular filtration < 45 mL/min/1.73 m2  
(CKD-EPI); **Including post-procedural antithrombotic mana-
gement; ASA — acetylsalicylic acid; CABG — coronary artery by- 
-pass grafting; CCS — chronic coronary syndrome; NSTEMI — 
non-ST segment elevation myocardial infarction; PCI — percutane-
ous coronary intervention; STEMI — ST-segment elevation myo-
cardial infarction
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treated this with aggressive post-dilatation (using 
an OPN™ non-compliant balloon at high-pressure, 
> 30 atm) and implantation of another DES (Xience™ 
4.0 × 18 mm), also see Supplemental Figure 1. 
A total of 5 patients had TVR, and 1 patient died 
30 days after PCI due to non-cardiovascular causes.
Discussion
We analyzed outcomes of a cohort of patients 
requiring CS implantation for treatment of coronary 
aneurysms, perforations, or dissections and who 
were managed with a novel hybrid approach aim-
ing to bury the CS behind a contemporary DES. 
This strategy appears to be safe and associated 
with excellent short- and long-term results in this 
registry, including a very low risk for TLR.
Coronary CS often comprises life-saving bail-
out devices in the setting of significant coronary 
artery perforation, in order to seal the perforated 
site. However, one needs to take into account the 
fact that residual endoleaks remain a concern and 
may ultimately lead to pericardial effusion and tam-
ponade [3, 19]. This may even be encountered with 
some delay [3, 19]. Of note, previously published 
series including patients who experienced coronary 
perforations and who were treated with the implan-
tation of a CS have demonstrated that a second or 
a third device is required in up to 20% cases to 
cover those endoleaks [20, 21]. In this context, 
the main mechanisms responsible for CS failure 
probably reflect the difficulty in achieving complete 
apposition — even with adequate post-dilatation —
and/or the lack of radial strength [19]. In our series 
2 out of 13 patients with coronary perforation (15%) 
had a pericardial tamponade, requiring pericardio-
centesis. In both patients, the initial strategy was to 
treat the coronary perforation with the implantation 
of CS only, but the presence of tamponade led to 
a change of strategy and the additional implanta-
tion of a DES to close the endoleak. Interestingly, 
in both cases endoleaks were barely visible on 
coronary angiography. Our approach of covering 
the CS completely with a DES addresses some 
of the aforementioned mechanical challenges and 
enhances stent apposition and reduces the chance 
of an endoleak requiring additional CS to seal 
a coronary perforation, which is also highlighted 
in Figure 3. 
Compared to previous studies, which indi-
cated high rates of TLF and TVR (5–25%) during 
short- and long-term follow-up (> 12 months), our 
results implicate that better outcomes (TLF rate 
< 5%) might be achieved after implantation of CS 
devices by applying the presented hybrid approach 
[3, 6, 7, 22–24]. 
Our data should be interpreted cautiously and 
considered as hypothesis-generating. Considering 
possible explanations for the rather favorable out-
comes that we observed in our cohort of patients 







No calcification 4/23 (17%)
Mild calcification 2/23 (9%)
Moderate calcification 6/23 (26%)
Severe calcification 11/23 (48%)
Chronic total occlusion 5/23 (22%)
Indication for covered stent use:
Coronary aneurysm 7/23 (30%)
Coronary perforation 13/23 (57%)
Type 2 perforation 9/13 (69%)
Type 3 perforation 4/13 (31%)
Aorto-ostial dissection 3/23 (13%)
Pericardial tamponade 2/23 (9%)
Covered stent devices:
No. of devices used 24
Papyrus™ 13/23 (55%)
BeGraft™ 10/23 (44%)
Size [mm] 3.6 ± 0.6
Length [mm] 19.1 ± 3.8
Implantation pressure [atm] 13 ± 2
Drug-eluting stent devices:




Size [mm] 3.6 ± 0.5
Length [mm] 30.2 ± 7.7
Post-dilatation balloon size [mm] 3.9 ± 0.4
Post-dilatation pressure [atm] 19 ± 6
Combination of covered stent and DES:
3 layers (DES/covered stent/DES) 11/23 (48%)
2 layers (covered stent/DES) 12/23 (52%)
DES — drug-eluting stents; EES — everolimus-eluting stent; No. 
— number; LAD — left anterior descending artery; LCX — left 
circumflex; LM — left main; RCA — right coronary artery; SES — 
sirolimus-eluting stent
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Figure 1. Treatment of a coronary aneurysm using a combination of a covered and drug-eluting stent. A. This panel 
demonstrates a significant left main stenosis (90%) followed by a large aneurysm. The aneurysm was initially sealed 
with a covered stent (Papyrus™ 3.5 × 15 mm). A drug-eluting stent (Xience™ 3.5 × 28 mm) was then implanted over 
the covered stent and post-dilated with a 4.0 mm non-compliant balloon at 18 atm achieving a good result (B). Follow-
up coronary angiography was performed 6 months later (C) showing a complete exclusion of the aneurysm and no 
in-stent restenosis. D. This was confirmed by optical coherence tomography demonstrating good healing, including 
coverage of all struts and only minimal neointimal hyperplasia.  
Figure 2. Sealing of a coronary perforation using a hybrid approach combining covered and drug-eluting stents (DES). 
A. A chronic total occlusion of the right coronary artery (RCA). Retrograde recanalization was performed, (B) but after 
a DES (Xience™ 3.5 × 28 mm) was implanted, a large coronary perforation was observed (Ellis type III) (C). Balloon 
occlusion did not stop the bleeding, and the perforation was consecutively sealed with a Papyrus 3.5 × 20 mm cov-
ered stent. The covered stent was then buried using a Xience™ 3.5 × 38 mm DES, which led to an angiographically 
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treated with CS, we think that the following three 
mechanisms may play an important role: (I) although 
we did not routinely perform intravascular imag-
ing to guide implantation, it is plausible that the 
additional implantation of a DES leads to a larger 
final lumen; (II) the presence of 2 layers of stents 
might provide enhanced radial strength, especially 
in fibro-calcific lesions, and therefore improved stent 
expansion; (III) additionally, a good stent expansion 
and apposition leads to enhanced laminar flow, which 
may limit the development of neoatherosclerosis 
and lower the risk for acute and subacute ST. 
As mentioned before, the healing response 
after implantation of a prosthetic graft is compli-
cated and involves a complex interplay between 
pro-thrombotic processes, and growth of extracel-
lular and cellular matrix [8]. Additionally, acute 
vessel injury leads by itself to a healing response 
with neointimal hyperplasia [11]. The presence of 
a DES seems to positively affect these processes 
— vascular healing was excellent in our patients, 
as demonstrated in Figures 1 and 2. Interestingly, 
even in patients treated with 3 layers of stent 
(DES-CS-DES) we did not observe a signal of ISR 
or ST, which indicates that the luminal presence of 
DES might contribute to a more controlled vascular 
healing response.
Limitations of the study
We understand these results have some limita-
tions and should be interpreted cautiously because 
they derive from a single center registry study. 
Also, we lack a comparison group. Therefore, more 
prospective and follow-up data are required to con-
firm our results. Also, it remains uncertain if our 
approach also applies to other coronary CS devices, 
because we only used polytetrafluoroethylene and 
polyurethanes containing devices.
Conclusions
This study suggests that rates of ST and ISR 
may be improved if CSs are overstented (“buried”) 
under contemporary DESs. If confirmed in fur-
Figure 3. Elimination of an endoleak after implantation of a covered stent (CS) by overstenting (“burying”) it with 
a drug-eluting stent (DES).
Table 4. Short- and long-term outcomes.
1 month (n = 23) ≥ 12 months (n = 19)
Myocardial infarction 1/23 (4%) 1/19 (5%)
Target vessel revascularization 1/23 (4%) 5/19 (26%)
Target lesion revascularization 0/23 (0%) 1/19 (5%)
Probable or definite stent thrombosis 0/23 (0%) 0/19 (0%)
Death:
Cardiovascular cause 0/23 (0%) 0/19 (0%
Other cause 1/23 (4%) 1/19 (5%)
Coronary 
perforation
CS implanted to cover the perforation. 
CS not perfectly apposed 
despite postdilatation
DES implanted through and 
over CS to enable apposition 
of CS on both ends
Endoleak present Endoleak sealed
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ther studies, this approach could help to improve 
short- and long-term outcomes of coronary CS 
implantation. 
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